Sign inCreate account

Report workspace

Add to folder
NCT00184054TERMINATEDanonymous

Phase II Trial of Arsenic Trioxide With Ascorbic Acid in the Treatment of Adult Non-APL Acute Myelogenous Leukemia

Sponsor

Source record

University of Southern California

Phase

Source record

Phase 2

Modality

AI-normalized

small molecule

Target

AI-normalized

Arsenic trioxide targets multiple pathways involved in apoptosis and differentiation in cancer cells, particularly through the induction of reactive oxygen species (ROS) and modulation of various signaling pathways.

Indication / condition

AI-normalized

Acute Myelogenous Leukemia

Intervention

Source record

Arsenic Trioxide (ATO), Ascorbic Acid

Related intelligence directories

Indication directory: Acute Myelogenous LeukemiaModality directory: small moleculeTarget directory: Arsenic trioxide targets multiple pathways involved in apoptosis and differentiation in cancer cells

Source & freshness

Source record

NCT ID

NCT00184054

Original source

ClinicalTrials.gov

Source last updated

Jul 25, 2014

Ingested at

Jun 19, 2026

Internal sync

Jun 19, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT00184054

Title

Phase II Trial of Arsenic Trioxide With Ascorbic Acid in the Treatment of Adult Non-APL Acute Myelogenous Leukemia

Sponsor

University of Southern California

Status

TERMINATED

Phase

Phase 2

Condition raw

Acute Myelogenous Leukemia

Condition normalized

Acute Myelogenous Leukemia

Modality raw

small molecule

Modality normalized

small molecule

Target raw

Arsenic trioxide targets multiple pathways involved in apoptosis and differentiation in cancer cells, particularly through the induction of reactive oxygen species (ROS) and modulation of various signaling pathways.

Target normalized

Arsenic trioxide targets multiple pathways involved in apoptosis and differentiation in cancer cells, particularly through the induction of reactive oxygen species (ROS) and modulation of various signaling pathways.

Interventions

Arsenic Trioxide (ATO), Ascorbic Acid

Public preview

Source record

The combination of arsenic trioxide and ascorbic acid presents a novel therapeutic approach for treating refractory non-APL acute myelogenous leukemia (AML). Given the limited treatment options for this patient population, successful outcomes could position this combination as a competitive alternative in the AML market. However, the trial was terminated due to competing studies, which may indicate a saturated or rapidly evolving landscape for AML therapies. Further diligence is required to assess ongoing studies and potential market entry strategies.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Early access offer

Subscribe with code FOUNDERS5 for a 5-day premium trial.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Phase II Trial of Arsenic Trioxide With Ascorbic Acid in the Treatment of Adult Non-APL Acute Myelogenous Leukemia

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 19, 2026

NCT ID

NCT00184054

Status

TERMINATED

Phase

Phase 2

Sponsor

University of Southern California

Executive brief

Investment-Ready Snapshot

The combination of arsenic trioxide and ascorbic acid presents a novel therapeutic approach for treating refractory non-APL acute myelogenous leukemia (AML). Given the limited treatment options for this patient population, successful outcomes could position this combination as a competitive alternative in the AML market. However, the trial was terminated due to competing studies, which may indicate a saturated or rapidly evolving landscape for AML therapies. Further diligence is required to assess ongoing studies and potential market entry strategies.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedJul 25, 2014
Internal syncJun 19, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT00184054

Indication

Acute Myelogenous Leukemia

Modality

small molecule

Target

Arsenic trioxide targets multiple pathways involved in apoptosis and differentiation in cancer cells, particularly through the induction of reactive oxygen species (ROS) and modulation of various signaling pathways.

Intervention

Arsenic Trioxide (ATO), Ascorbic Acid

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.